The PARP4 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Raji B lymphocyte line. This model provides a loss-of-function system for PARP4, generated through CRISPR/Cas9-mediated gene disruption without single-cell cloning. The heterogeneous polyclonal format preserves genetic diversity, offering a robust platform for functional studies and drug screening applications.
Raji cells are EBV-positive B lymphocytes originally from a Burkitt lymphoma patient, exhibiting an activated B-cell phenotype. Widely used as a B-cell malignancy model, they support studies in antibody production and adaptive immunity. EBV immortalization ensures continuous suspension growth, and the line??s intrinsic chemoresistance, mediated by drug efflux transporters and DNA repair pathways, makes it particularly suitable for investigating drug resistance mechanisms.
PARP4 encodes a poly(ADP-ribose) polymerase integral to vault ribonucleoprotein particles, comprising major vault protein (MVP), vault RNA (vRNA), and telomerase-associated protein 1 (TEP1). Activated by DNA damage, cellular stress, and mitogenic signals, PARP4 catalyzes poly(ADP-ribosyl)ation, influencing vault stability and function. Downstream, it regulates drug efflux pumps such as ABCB1 and DNA repair factors, linking vault-mediated transport to chemoresistance. Through these interactions, PARP4 coordinates cellular responses to stress and drug exposure in B-cell contexts.
In Raji cells, PARP4 knockout is expected to disrupt vault particle-mediated transport, potentially enhancing sensitivity to chemotherapeutics. The interplay between PARP4, MVP, vRNA, and efflux pumps underpins drug resistance in Burkitt lymphoma. This polyclonal knockout model allows dissection of vault-dependent drug sequestration and efflux mechanisms under genotoxic stress, facilitating identification of vulnerabilities for therapeutic targeting in lymphoma.
Researchers can use this model in diverse assays: drug sensitivity profiling (MTT, CellTiter-Glo) to measure chemosensitivity shifts; flow cytometry for apoptosis and cell cycle analysis; Western blotting and RT-qPCR to verify knockout efficiency and pathway modulation; and co-immunoprecipitation with immunofluorescence to assess vault complex integrity. RNA-seq enables transcriptomic profiling, and vault particle isolation supports biochemical studies. Applications encompass drug resistance mechanism investigation, lymphoma therapeutic development, vault biology, chemosensitivity screening, and DNA damage response research. For additional information, please contact Ascent Research.
